The inhibitory PD-1/PD-L1 checkpoint pathway confers a significant immunosuppressive protection in autoimmune diseases and many chronic inflammatory states although in cancers and fibrotic diseases it is associated with major detrimental effects [14, 21, 22]. This evidence concerns the gene PDCD1 and cancer.